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High concentrations of circulating biogenic catecholamines often exist during the course of several
cardiovascular disorders. Additionally, coronary dysfunctions are prominent and frequently related to
the ischemic and reperfusion phenomenon (I/R) in the heart, which leads to the release of large amounts
of catecholamines, namely adrenaline, and to a sustained generation of reactive oxygen species (ROS).
Thus, this work aimed to study the toxicity of adrenaline either alone or in the presence of a system
capable of generating ROS [xanthine with xanthine oxidase (X/XO)], in freshly isolated, calcium tolerant
cardiomyocytes from adult rats. Studies were performed for 3 h, and cardiomyocyte viability, ATP level,
lipid peroxidation, protein carbonylation content, and glutathione status were evaluated, in addition to
the formation of adrenaline’s oxidation products and quinoproteins. Intracellular GSH levels were time-
dependently depleted with no GSSG formation when cardiomyocytes were exposed to adrenaline or to
adrenaline with X/XO. Meanwhile, a time-dependent increase in the rate of formation of adrenochrome
and quinoproteins was observed. Additionally, as a new outcome, 5-(glutathion-S-yl)adrenaline, an
adrenaline adduct of glutathione, was identified and quantified. Noteworthy is the fact that the exposure
to adrenaline alone promotes a higher rate of formation of quinoproteins and glutathione adduct, while
adrenochrome formation is favored where ROS production is stimulated. This study shows that the redox
status of the surrounding environment greatly influences adrenaline’s oxidation pathway, which may
trigger cellular changes responsible for cardiotoxicity.
Introduction
An estimated one-third of total global deaths result from the
various forms of cardiovascular diseases, ischemic heart disease
being the main cause (1). Although they were considered
diseases of developed countries, since half of all deaths in the
United States are related to cardiovascular diseases (2), a new
reality is emerging, and it is estimated that by 2010 cardiovas-
cular diseases will be the leading cause of death in developing
countries (1).
When a stressful stimulus occurs, adrenaline and noradrena-
line are released, throughout the nervous system and adrenal
medulla (3). The cardiac sympathetic nerves are preferentially
stimulated in severe heart failure, which includes a 50-fold
increase in the rate of spillover of noradrenaline, but also a large
release of the sympathetic co-transmitters, adrenaline and
neuropeptide Y (4). During an ischemic phenomenon, the
concentrations of noradrenaline and adrenaline rise progressively
in the interstitial myocardial fluid (3, 5). Elevated concentrations
of circulating catecholamines are also found in arrhythmias,
myocardial necrosis (3, 5), heart failure (4), exercise (6),
pheochromocytoma (7), hypoglycemia, hemorrhagic hypoten-
sion, circulatory collapse, and distress (8). Additionally, cate-
cholamines have been widely used for decades in cardiovascular
therapy (adrenaline has been used for cardiopulmonary resus-
citation for more than 100 years) (9, 10).
Ischemic and reperfusion phenomenon (I/R), a coronary
dysfunction, is associated with oxidative stress. In fact, in post-
ischemic myocardium, ROS 1 are formed at an accelerated rate
(11–13), playing a major role in pathogenesis. Cardiac myocytes,
endothelial cells, and infiltrating neutrophils contribute to ROS
production (2). High levels of ROS are also found in exercise
(14), and in many pathological conditions, such as inflammation
(15, 16), neurodegeneration (17), and aging (18).
Although the toxicity of catecholamines is mainly related to
the stimulation of adrenoreceptors, there is a growing body of
evidence which shows that their oxidation is also responsible
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for cardiotoxicity (13, 19, 20). The oxidation of catecholamines
at physiological pH seems to occur very slowly; however, it
increases considerably by enzymatic or metal catalysis (19, 21, 22)
or in the presence of superoxide anion (O2•-) (23). Therefore,
oxidation of adrenaline in vivo is possible in some circum-
stances, as in I/R. In accordance, products of this oxidation have
been described in the heart, skeletal muscle, liver, and blood
(20). The oxidative pathway of catecholamines generates various
highly reactive intermediaries, like o-quinones, aminochromes,
aminolutins, and melanins (19), which can react with external
nucleophilic groups, especially SH groups, present in cysteine,
glutathione, and proteins (24–26) or OH and NH2 groups also
in proteins (27). For instance, adrenochrome is capable of
inhibiting the activity of several enzymes (19, 28), thus greatly
modifying cellular metabolism (20). The interaction of adreno-
chrome with SH groups and the induced depletion of oxygen,
ascorbate, and glutathione may cause noxious effects toward
the cellular function and defenses (28).
In addition, the conjugation of oxidation products of cate-
cholamines with GSH is no longer considered a simple
detoxification route. In fact, these adducts have been reported
to induce toxicity. Actually, they seem to be involved in the
pathogenesis of Parkinson’s disease (24, 29) and in the toxicity
of the illicit drugs MDMA (3,4-methylenedioxymethamphet-
amine) (30, 31) or methamphetamine (26).
Our work aimed to provide new insight into the toxicity
induced by adrenaline, ROS, and their concomitant effects in
freshly isolated calcium tolerant cardiomyocytes obtained from
adult rat, a suitable in vitro model for evaluating the mechanisms
involved in the toxicity toward these muscle cells (32, 33). The
X/XO system was used to mimic an oxidative stress environ-
ment, which, as stated above, is present in several pathologies,
some of those with concomitant release of large quantities of
catecholamines.
The studies on tolerant calcium cardiomyocytes were per-
formed for a maximum period of 3 h, and cellular viability,
oxidation products of adrenaline, glutathione status, quinopro-
teins, and glutathione adduct were evaluated during the time
course of the experiments to determine the mechanistic pathway
of adrenaline’s oxidation when alone and compare it with that
in the presence of ROS.
Materials and Methods
Animals. Adult male Sprague-Dawley rats (Charles River
Laboratories, Barcelona, Spain) weighing 250–350 g were used.
The animals were housed in cages with a temperature- and
humidity-controlled environment. Food and water were provided
ad libitum, and animals were subjected to a 12 h light–dark cycle.
Animal experiments were licensed by the Portuguese General
Directory of Veterinary Medicine. Housing and experimental
treatment of the animals were in accordance with the Guide for
the Care and Use of Laboratory Animals from the Institute for
Laboratory Animal Research (ILAR 1996). The experiments
complied with current Portuguese laws.
Chemicals. All reagents used in this study were of analytical
grade. Collagenase type II was obtained from Worthington (Lake-
wood, NJ). Collagenase (type IA), bovine serum albumin (fraction
V), N-(2-hydroxyethyl)piperazine-N-(2-ethanesulfonic acid) (HEPES),
reduced glutathione (GSH), oxidized glutathione (GSSG), glu-
tathione redutase (GR, EC 1.6.4.2), 2-vinylpyridine, reduced
-nicotinamide adenine dinucleotide phosphate (-NADPH), re-
duced -nicotinamide adenine dinucleotide (-NADH), 5,5-dithio-
bis(2-nitrobenzoic acid) (DTNB), adenosine triphosphate (ATP),
pyruvic acid, phenylmethanesulfonyl (PMSF), nitroblue tetrazolium
(NBT), 1-chloro-2,4-dinitrobenzene, 1-octanesulfonic acid, mush-
room tyrosinase, γ-glutamyltranspeptidase (γ-GT, EC 2.3.2.2),
luciferase, luciferin, and all reagents for enzymatic determinations
were obtained from Sigma-Aldrich (St. Louis, MO). Citric acid,
methanol (gradient grade), perchloric acid, and all other chemicals
were purchased from Merck (Darmstadt, Germany).
5-(Glutathion-S-yl)adrenaline Synthesis and RMN Anal-
ysis. The synthesis of the adduct of adrenaline with GSH followed
previously published methods (34) for other catecholamine–GSH
adducts.
To a solution of (-)-adrenaline (0.010 g, 5.46 × 10-5 mol) in
sodium phosphate buffer (20 mL, pH 7.4, 50 mM) at 25 °C was
added mushroom tyrosinase (4000 units, 200 units/mL of buffer).
The solution became red, indicating the formation of o-quinone.
GSH (0.0335 g, 1.09 × 10-4 mol) was added, and the red-colored
solution changed with time to yellow (19 h). At the terminus of
the reaction, 1 mL of 88% formic acid was added, and the solution
was carefully concentrated by rotary evaporation without heating.
The purification of the product was performed by reverse-phase
RP-18 modified silica column chromatography (Merck KGaA) first
with water (150 mL) and then 10 × 10 mL of 10% methanol
followed by 10 × 10 mL of 20% methanol. Each fraction was
checked for the presence of adduct using a UV–vis detector.
Fractions containing maxima at 260 and 292 nm were separated
and carefully evaporated to dryness. Due to the fact that glutathione
was difficult to separate from the adrenaline adduct, further
purification by HPLC was necessary using a LiChrospher 100 RP-
18 column (Merck KGaA), with two mobile-phase solvents. Solvent
A was prepared by adding concentrated trifluoroacetic acid (TFA)
to deionized water until the pH reached 2.5. Solvent B was prepared
by adding TFA to a 1:1 mixture of acetonitrile (MeCN) and
deionized water until the pH reached 2.6. The mobile phase was
made of solvents A and B, and the following gradient was used:
100 to 85% solvent A from 0 to 25 min, 85 to 65% solvent A from
25 to 32 min, 65 to 0% solvent A from 32 to 37 min, and 100%
solvent A from 37 to 42 min. The compounds eluted within 10
min. The peaks were monitored at 290 nm. 5-(Glutathion-S-
yl)adrenaline (0.006 g) was obtained as an oil in 22.5% yield: 1H
NMR (D2O) δ 2.07 (2H, m, Glu-), 2.41 (2H, m, Glu-γ), 2.67
(3H, s, N-CH3), 3.14 (3H, m, Cys-, CH2), 3.28 (1H, m, Cys-),
3.75 (1H, s, Gly-R), 3.91 (2H, m, Glu-R), 6.83 (1H, s, ArH2′/6′),
6.93 (1H, s, ArH2′/6′); MALDI-TOF (sinapinic acid) m/z 489.5
[MH]+, 511.5 [M + Na]+.
Calcium Tolerant Cardiomyocytes Isolated from Adult
Rat. Calcium tolerant cardiomyocytes were isolated by Langendorff
retro perfusion of adult rat heart as previously described (35, 36),
with some modifications. The procedure was based on (i) successive
treatments with calcium free medium and (ii) digestion with
collagenases (collagenase type II and collagenase type IA in a 200
µM calcium-modified Krebs–Henseleit buffer solution), followed
by (iii) gentle mechanical disaggregation. Calcium tolerant cardi-
omyocytes were obtained by gradual re-introduction of calcium until
a final concentration of 1 mM. All steps were performed in modified
Krebs–Henseleit buffer containing 102 mM NaCl, 4 mM KCl, 1
mM MgSO4, 10 mM glucose, 5.5 mM NaHCO3, 0.9 mM KH2PO4,
and 22 mM HEPES (pH adjusted to 7.2–7.4) saturated with a
gaseous stream of carbogen (95% O2 and 5% CO2). At the
beginning of the experiments, cell viability was always greater than
60%, evaluated by the lactate dehydrogenase (LDH) leakage assay
and by microscopic evaluation of cardiomyocyte morphology. The
obtained viability is in accordance with previous reports for calcium
tolerant cardiomyocytes (37–39). This viability was obtained after
a 5 min preincubation at 37 °C to guarantee the correspondence
between values obtained via manual counting and a LDH leakage
assay. Incubations were performed in a water bath at 37 °C, using
a density of 2.5 × 105 viable cells/mL in the modified Krebs–
Henseleit buffer supplemented with 1 mM CaCl2 (pH 7.4) and
saturated with an air stream of carbogen, every hour. After a
preincubation for 30 min at 37 °C, the compounds were tested using
the following protocol: (i) control cells, with no treatment; (ii) cells
incubated with adrenaline (ADR) alone; (iii) cells incubated with
ADR and X/XO; and (iv) cells exposed to the X/XO system alone.
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The final concentrations were as follows: 0.5 mM ADR (unless
otherwise mentioned), 0.1 mM xanthine, and 0.01 unit/mL xanthine
oxidase.
Sample Treatment. At incubation times of 0, 1, 2, and 3 h,
determinations were performed directly using the cardiomyocyte
suspension or after centrifugation at 18g for 2 min, for separation
of supernatant and pellet, as previously described (38). The
supernatant is termed the incubation medium. The pellet was washed
two times with 1 mL of modified Krebs–Henseleit buffer supple-
mented with 1 mM CaCl2, centrifuged at 18g for 2 min, and finally
treated according to the chemical and biochemical determinations
for cardiomyocytes. Washing solutions obtained after centrifugation
were rejected.
Cell Viability Assays. 1. Lactate Dehydrogenase Leakage
Assay. The LDH leakage assay was directly performed in the
cardiomyocyte suspensions to evaluate the level of cell injury at
time zero (immediately after addition of the compounds) and after
incubation for 3 h in all treatments, as previously described (38).
2. Morphology. The percentage of rod-shaped cells was
determined using a Neubauer chamber, as previously described (40).
Cells with a length/width ratio of >4 were considered rod-shaped
cells.
Measurement of Total GSH (GSHt), GSH, and GSSG
Levels. The cardiomyocyte and incubation medium levels of GSH
and GSSG were measured by the DTNB–GSSG redutase recycling
assay, as previously described (41). Both the incubation medium
and cardiomyocytes were acidified to a final concentration of 5%
HClO4 and centrifuged, and the supernatant obtained was used for
the measurements.
Determination of GPx, GR, and GST Intracellular Activi-
ties. For the determination of glutathione peroxidase (GPx),
glutathione redutase (GR), and glutathione S-transferase (GST)
activities, aliquots of the cell suspension were sonicated for 12 s at
intensity 4 in a VibraCell sonicater (Sonics & Materials Inc.,
Danbury, CT) and then centrifuged at 16000g for 10 min. The GPx,
GR, and GST activities were determined in the supernatant that
was obtained, as previously described (42). Briefly, GR activity
was determined by following NADPH oxidation at 340 nm during
the reduction of GSSG to GSH. Selenium-dependent GPx activity
was determined by following NADPH oxidation at 340 nm after
reduction of GSSG by GR. Finally, GST activity was determined
by following the formation of the GSH conjugate with 1-chloro-
2,4-dinitrobenzene, which was monitored at 340 nm. All measure-
ments were performed in triplicate in a 96-well plate reader.
Measurement of Cellular and Extracellular ATP Levels. The
incubation medium and cardiomyocytes were acidified to a final
concentration of 5% HClO4 and centrifuged, and the supernatant
obtained was used for the measurements. The level of ATP was
measured by the bioluminescence test based on the work of De
Luca et al. (43).
Assessment of Protein Carbonylation. Protein carbonyl groups
were quantified in cardiomyocytes, as described by Levine et al.
(44), by reaction with 2,4-dinitrophenylhydrazine (DNPH).
Protein Determination. The protein levels were determined as
previously described by Lowry (45). Protein content for quinopro-
teins was determined by the method described by Bradford (46).
Assessment of Lipid Peroxidation. The extent of lipid peroxi-
dation in suspension cells was measured by the assay for thiobar-
bituric acid reactive substances (TBARS) at 535 nm, as previously
described (42).
Assessment of Protein-Bound Quinones (Quinoproteins). For
the assessment of protein–bound quinones in cardiomyocytes, the
NBT/glycinate colorimetric assay was performed, which is based
on the method described by Paz et al. (47), with a few adaptations.
The cardiomyocytes were lysed in 200 µL of ice-cold RIPA buffer,
supplemented with 5 mM PMSF. The samples were sonicated at
intensity 4 in the VibraCell sonicater for 3 s, and the whole protein
content was quantified by the Bradford method (46), using BSA
as a protein standard. Twenty-five micrograms of the lysates in
RIPA buffer was added to 240 µL of a 2 M potassium glycinate
(pH 10) solution. To this last solution was added 500 µL of NBT
reagent [0.24 mM NBT in 2 M potassium glycinate (pH 10)]. The
reaction was performed for 3 h at room temperature in the dark,
after which the absorbance was read at 530 nm in a 96-well plate
reader.
HPLC-DAD/EC Analysis. Adrenochrome and adrenaline in the
incubation medium were quantified by HPLC (Waters model 2690)
with a photodiode array detector (DAD), at 279 nm (for catechola-
mine) and 300 nm (for aminochrome), as previously described (40).
The quantification of adrenaline levels in the cardiomyocytes and
of adrenaline–GSH adduct was performed with the same HPLC
instrument equipped with an electrochemical detector (EC), as
previously described (48).
The incubation medium and cardiomyocytes, these last after being
washed two times as described in Sample Treatment, were acidified
to a final concentration of 5% HClO4 and centrifuged, and the
supernatant obtained was used for the measurements. After
sampling, the acidic samples were supplemented with ascorbic acid
(5 mM, final concentration), to avoid further formation of the GSH
adduct. Storage was at -80 °C, with HPLC-EC analysis being
performed within 24 h of treatment. Previous studies were
performed to guarantee the stability of the adduct and to avoid
chemical formation of the adduct during storage.
Quantitative measurements of adrenaline content (in the cells),
as well as of the GSH–adrenaline adduct (in the cells and incubation
medium), were carried out by interpolation of standard curves
obtained by injection of standard solutions of adrenaline and the
GSH–adrenaline adduct, by a previously validated method (48).
To confirm the presence of the GSH adduct, cardiomyocytes and
incubation medium aliquots were spiked with 5-(glutathion-S-
yl)adrenaline standard. Moreover, to strengthen identification of the
GSH conjugate, aliquots were treated with γ-glutamyltranspeptidase
(γ-GT), according to the method of Carvalho et al. (41), with minor
modifications. This procedure allowed the identification of GSH
adducts, since γ-GT cleaves the γ-glutamyl bond of GSH (49).
The cardiomyocytes were sonicated (12 s at intensity 4 in the device
described above) and then treated with γ-GT (final concentration
of 4 IU in Krebs–Henseleit buffer) for 5 min before protein
precipitation with 5% HClO4 (final concentration). Incubation
medium samples were placed in contact with γ-GT (final concen-
tration of 4 IU in Krebs–Henseleit buffer) for 5 min at room
temperature before protein precipitation with 5% HClO4 (final
concentration). Both samples were then centrifuged for 10 min at
16000g, and the supernatant obtained was injected into the HPLC-
EC system.
Statistical Analysis. Results are given as means ( the standard
deviation (SD) from six independent experiments with suspensions
of cardiomyocytes proceeding from six different rats. Nonparametric
tests were used. Statistical comparisons between groups were
performed with a Kruskal–Wallis test (one-way ANOVA on Ranks)
followed by the Student–Newman–Keuls post hoc test, once a
significant p had been obtained.
When only two treatment groups were compared, the Mann–
Whitney Rank Sum test was used. Details of the statistical analysis
are described in each figure legend. Significance was accepted at p
values of <0.05.
Results
Changes in the Concentration of Adrenaline and
Adrenochrome. The measurement of adrenaline and adreno-
chrome levels was performed in cardiomyocytes and incubation
medium of cell suspensions incubated with ADR or with ADR
and X/XO. In control or X/XO cells, no adrenaline or adreno-
chrome was detected.
In cardiomyocytes after incubation for 3 h, a significantly
higher concentration of adrenaline was found in the ADR group
(12 ( 1 nmol of ADR/2.5 × 105 cardiomyocytes) when
compared with the group with ADR and X/XO (8 ( 1 nmol of
ADR/2.5 × 105 cardiomyocytes).
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In the incubation medium, adrenaline was quantified each
hour during the 3 h incubation. The concentration of adrenaline
decreased rapidly from its initial value of 0.5 mM in both
treatments, although more rapidly in suspensions exposed to
ADR and X/XO (Figure 1A). The difference between treatments
was statistically significant as early as 1 h. After incubation for
3 h, the concentration of adrenaline was 321 ( 52 and 222 (
80 µM in suspensions with ADR and with ADR and X/XO,
respectively.
In the incubation medium, the decrease in adrenaline levels
was accompanied by a time-dependent increase in the adreno-
chrome levels. This result was more evident in the group with
ADR and X/XO, where values of adrenochrome reached 155
µM, at 3 h (Figure 1B).
The adrenochrome peak was not detected in the cardiomyo-
cytes in ADR group or ADR and X/XO group.
Adrenaline Oxidation Products Bind to Intracellular
Proteins. The protein-bound quinone products (quinoproteins)
present in cardiomyocytes were evaluated hourly, for all the
treatments (Figure 1C). The measurements showed no significant
differences between control cells and the X/XO group, at all
time points (data not shown). Moreover, in the presence of ADR
and ADR with X/XO, quinoprotein levels increased steadily in
a time-dependent manner (Figure 1C). Quinoprotein levels in
the ADR cells at 2 and 3 h were 2 and 3 times higher,
respectively, than in control. In the cells with ADR and X/XO,
at 3 h, the quinoprotein content was double control levels.
Alteration in Glutathione Status. In Figure 2, the levels of
GSHt (Figure 2A), GSH (Figure 2B), and GSSG (Figure 2C)
in cardiomyocytes, during the time course of a 3 h incubation
in control, ADR, and ADR and X/XO cells, can be observed.
There were no significant differences between the X/XO group
and control (data not shown). However, the exposure to ADR
caused a decrease in GSHt levels (Figure 2A), when compared
to control. Additionally, the group with ADR and X/XO showed
a more prominent decline in the content of both GSHt (Figure
2A) and GSH (Figure 2B). The differences between ADR and
ADR with X/XO became significant as early as 1 h for GSHt
(Figure 2A) and 2 h for GSH (Figure 2B). It is worth mentioning
that the levels of GSSG in cardiomyocytes did not suffer any
alteration (Figure 2C) at any time point or group that was
analyzed.
In addition, in the incubation medium, the levels of GSH and
GSSG measured for all treatments showed no significant
differences among them (data not shown).
Lower concentrations of ADR (0.25 and 0.1 mM) were also
tested to determine variations of GSH and GSSG levels. No
Figure 1. Levels of adrenaline (A) and adrenochrome (B) in incubation
medium and of quinoproteins in cardiomyocytes (C) of cell suspensions
incubated with 0.5 mM ADR and 0.5 mM ADR with X/XO. Results
are presented as means ( SD from six different experiments. Statistical
comparisons were made using Kruskal–Wallis test followed by the
Student–Newman–Keuls post hoc test: *p < 0.05 and **p < 0.01 vs
control; #p < 0.05 and ##p < 0.01 for ADR vs ADR and X/XO groups;
and δp < 0.05 and δδp < 0.01 vs time zero.
Figure 2. Intracellular glutathione levels [total (A), reduced (B), and
oxidized (C)] in calcium tolerant rat cardiomyocytes: control, 0.5 mM
ADR, and 0.5 mM ADR with X/XO for 3 h. No statistical differences
were found for the X/XO system as an isolated treatment, when
compared with control (data not shown). Results are presented as means
( SD from six different experiments. Statistical comparisons were made
using Kruskal–Wallis test, followed by the Student–Newman–Keuls
post hoc test: *p < 0.05 and **p < 0.01 vs control; and #p < 0.05 and
##p < 0.01 for ADR vs ADR and X/XO groups.
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differences were registered among the groups when compared
to control groups (data not shown), at a maximum incubation
of 3 h.
The sampling homogeneity was confirmed by protein levels,
which remained fairly constant at all experimental times in each
assay (data not shown).
Adrenaline Conjugated with Glutathione: Formation of
5-(Glutathion-S-yl)adrenaline. The depletion of GSHt and
GSH with no GSSG formation may be explained by the
conjugation between GSH and oxidation products of adrenaline.
Thus, cardiomyocytes and incubation medium samples were
collected and analyzed by HPLC-EC for GSH–adrenaline adduct
detection, by a previously described method (48).
The 5-(glutathion-S-yl)adrenaline adduct was found in car-
diomyocytes and in the incubation medium in ADR group and
in ADR and X/XO group. The chromatographic peak was
confirmed as being 5-(glutathion-S-yl)adrenaline after co-elution
with a 5-(glutathion-S-yl)adrenaline standard. The sample was
also injected with and without addition of the 5-(glutathion-S-
yl)adrenaline standard, showing that the peaks have the same
retention time (Figure 3A). Additionally, the chromatographic
peak of this adduct completely disappeared when samples
(cardiomyocytes and incubation medium) were treated with
γ-GT, which can be observed in Figure 3B. Treatment with
γ-GT of the control or X/XO group showed no interfering peaks,
either in the incubation medium or in cardiomyocytes (data not
shown).
The levels of 5-(glutathion-S-yl)adrenaline were evaluated,
and a higher level of formation of the GSH adduct was observed
in cells incubated for 3 h with ADR [378 ( 48 pmol of
5-(glutathion-S-yl)adrenaline/2.5 × 105 cardiomyocytes] when
compared with ADR and X/XO [115 ( 32 pmol of 5-(glu-
tathion-S-yl)adrenaline/2.5 × 105 cardiomyocytes] (Figure 4),
which represents an increase of more than 3-fold in the first
group compared to the latter.
In the incubation medium, the same trend was also found,
since higher values of adduct were measured in the ADR group
(830 ( 139 pmol/mL), which represents around twice the levels
observed in the group with ADR and X/XO (433 ( 130 pmol/
mL) (Figure 4).
Of note, the presence of the referred adduct with lower
concentrations of adrenaline was also evaluated, after a 3 h
incubation of the cardiomyocyte suspensions. In both groups,
the lowest concentration of adrenaline that enabled the detection
of adduct in the cardiomyocytes was 25 µM.
Adrenaline Treatment Did Not Induce Changes in
Lipid Peroxidation, Protein Carbonylation, Activity of
Antioxidant Enzymes, or ATP Concentration. Incubation of
cardiomyocyte suspensions for 3 h with ADR, ADR and X/XO,
or just X/XO did not induce significant changes in cellular
viability or ATP content (data not shown). No differences were
found for lipid peroxidation and protein carbonylation.
The activity of three antioxidant enzymes, GR, selenium-
dependent GPx, and GST, was evaluated for all the treatments
after incubation for 3 h with no significant differences being
observed (data not shown).
Discussion
The findings of this work showed the ability of adrenaline to
undergo a complex oxidation process, which is influenced by
the presence of ROS. This oxidation process affects cardiomyo-
cyte homeostasis, contributing to adrenaline-induced cardiotoxic
effects. New insights concerning the toxicity of adrenaline can
be drawn from this study: (1) reactive oxidative products of
adrenaline were formed, specifically, adrenochrome; (2) adrena-
line exposure decreased the GSH levels in cardiomyocytes; (3)
the reactivity of adrenaline oxidation products enabled the
formation of quinoproteins and of a GSH–adrenaline adduct,
this last, for the first time detected in cells; and (4) the stability
of the intermediary quinone was intimately related to the
formation of the reactive products mentioned before and to the
microenvironment where the oxidation occurs.
Plasma levels of adrenaline in healthy volunteers at rest are
as low as 30 pM, while the level of noradrenaline reaches 1
nM (8, 50). However, any alteration in the metabolism of
catecholamines or disruption of their transport mechanisms
might lead to anomalously high concentrations of these sub-
stances (5). The concentrations of adrenaline in plasma greatly
increase as a result of adrenal stimuli (8). Namely, in pheo-
chromocytoma patients, plasma concentrations of adrenaline
were shown to range from 0.3 to 3.6 µM, while noradrenaline
concentrations can reach 50 µM (1.5-50 µM) (7).
Moreover, extra-adrenal adrenaline synthesis and phenyl-
ethanolamine N-methyltransferase have been reported in the
Figure 3. HPLC-EC chromatograms showing the peak corresponding
to the 5-(glutathion-S-yl)adrenaline formed within the cells incubated
with 0.5 mM ADR and X/XO for 3 h (A). The sample was injected
with and without addition of the 5-(glutathion-S-yl)adrenaline standard
(A), showing that the peaks have the same retention time. The peaks
were obtained from cells incubated with 0.5 mM ADR (B) before and
after treatment with γ-GT for 3 h. Treatment in control or in X/XO
groups with γ-GT showed no interfering peaks (data not shown).
Figure 4. Levels of 5-(glutathion-S-yl)adrenaline formed within the
myocytes and incubation medium of cardiomyocyte suspensions
incubated with 0.5 mM ADR and 0.5 mM ADR with X/XO. Statistical
comparisons, at 3 h, were made using the Mann–Whitney Ram Sum
test: ##p < 0.01 for ADR vs ADR and X/XO groups.
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heart, and an extensive uptake of adrenaline from the plasma
occurs in some pathologic conditions (8). Concentrations are
expected to be higher in the heart tissue than the ones reported
in the plasma, where the rate of clearance is higher.
In particular, it has been shown that, during heart ischemia,
the release of catecholamines becomes non-exocytotoxic and
is thought to involve the uptake of carrier-mediated efflux in
reverse of its normal transport direction (5), largely increasing
the concentration of those biogenic amines in the interstitial
space, where they can reach values of 4.7 nM (5). Furthermore,
sympathetic neurons can take up adrenaline from circulation
and release it upon stimulation in the heart (5). When the
enzymes responsible for their catabolism (monoamino oxidase
and catechol-o-methyltransferase) are unable to cope efficiently,
the catecholamine levels in the heart rise and the catecholamine
can undergo oxidation, which is catalyzed by trace metals and
several enzymes (19, 21, 22). The oxidation pathway of
adrenaline involves multiple steps (Figure 5). Adrenaline may
be converted to an unstable o-semiquinone that, after deproto-
nation and loss of a second electron, gives rise to the corre-
sponding o-quinone. At physiological pH, partial deprotonation
of the amine group of the side chain of adrenaline leads to an
irreversible 1,4-intramolecular cyclization, a reaction that occurs
through nucleophilic attack of the nitrogen atom at the 6 position
of the quinone ring, to give leucoadrenochrome, which is then
further oxidized to adrenochrome (19, 51). In vivo, this oxidation
pathway may be more complex, since other factors, such as
metal ions or other nucleophilic groups, can be involved (24).
Oxidative stress is a condition in which pro-oxidant metabo-
lites exert toxic effects due to their enhanced production and/
or an exhaustion in cellular protection mechanisms (52). There
is a growing body of evidence which shows that prolonged
ischemia reduces the defense mechanisms within the heart
against free radicals (53). Meanwhile, during reperfusion, ROS
can be formed above the neutralizing capability of the cells,
playing a major role in the pathogenesis of post-ischemic
reperfusion injury (11).
Since ROS are formed in I/R phenomena in vivo, an O2•--
generating system can be used to mimic an oxidative stress
condition (24, 54). In our work, X/XO was applied to freshly
isolated cardiomyocytes, since it is a system suitable for
generating ROS. This system was used to mimic the in vivo
Figure 5. Postulated pathway for the oxidation of adrenaline in cardiomyocytes and incubation medium (not all intermediates are shown, for
simplification). The oxidation process of adrenaline initially involves its conversion to o-quinone with an o-semiquinone intermediary in cardiomyocytes.
The o-quinone can react with GSH, to form the corresponding GSH conjugate, or react with other nucleophilic groups in the cells. Thus, the higher
stability of o-quinone where only adrenaline is present favors the formation of the GSH adduct and quinoproteins. The GSH adduct seems to be
transported out of the cells. Meanwhile, the o-quinone can undergo an irreversible 1,4-intramolecular cyclization, forming leucoadrenochrome. The
oxidation to adrenochrome of the unstable leucoadrenochrome is rapid, especially in the group where a ROS generating system (O2•-) is present.
The formation of adrenochrome is a reaction in which a total of two electrons are removed and adrenochrome semiquinone is the intermediate.
Adrenochrome formed in the cells can also suffer conjugation with cellular GSH, leading to its depletion, or polymerize into several other compounds.
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situation, as there are several works reporting an important role
of XO in the pathogenesis of I/R phenomena and other diseases
of the heart (55, 56). In cultured cardiomyocytes, Durot et al.
(54) used X/XO concentrations 0.1 mM per 0.01 unit/mL
reported to be found under pathophysiological conditions. At
those concentrations, X/XO produced O2•- for 10 min and also
small amounts of •OH radical. The GSH levels are not greatly
affected in our work by the presence of the X/XO system, since
thiols react slowly with O2•-, as previously reported in the
nervous system (24).
The functional consequences of the exposure to ROS largely
depend of the species that are present (54). Catecholamines react
amazingly fast with O2•- (23). The burst of ROS caused by
X/XO determines formation of adrenaline oxidation products,
resulting in the formation of semiquinone radicals, o-quinones,
and later adrenochrome (51) (Figure 5). Moreover, O2•- seems
to catalyze the conversion of adrenaline to adrenochrome by
acting as a propagating species in a cascade reaction during the
univalent oxidation of the catecholamine (57). Our results show
that adrenaline depletion was more enhanced in the group ADR
with X/XO both in the cardiomyocytes and in the incubation
medium (Figure 1A). In the incubation medium, the decrease
in adrenaline levels was accompanied by the evident increase
in adrenochrome concentration (Figure 1B), this effect being
more pronounced in cells incubated with ADR and X/XO. As
observed in a previous work (51), when adrenochrome is
generated and adrenaline still exists in solution, adrenochrome
seems to accelerate the oxidation of the remaining adrenaline.
The formation of adrenochrome has been reported in cardiac
diseases, such as those accompanied by leukocytic infiltration
(58), myocardial infarction, and cardiomyopathy (3). Unexpect-
edly, we could not find adrenochrome in the cardiomyocytes.
The high reactivity of adrenochrome toward various cellular
nucleophiles, such as GSH or proteins (28, 59), of the cardio-
myocytes may explain its rapid disappearance and also the lower
values for GSH observed in cells with ADR and X/XO. Previous
results in isolated heart seem to corroborate this binding ability,
since when heart is reperfused with radioactive adrenochrome,
approximately 50% of adrenochrome radioactivity remains in
the organ, indicating an irreversible binding to the tissues (19).
In addition, adrenochrome can undergo further structural
modifications throughout the oxidative pathway or rearrange
to other substances, forming adrenolutin or polymers (19).
Notwithstanding its toxicity, adrenochrome is reported to
inhibit lipid peroxidation (19). A reduced form of adrenochrome
(leucoadrenochrome or the corresponding semiquinone) can also
act as a particularly efficient antioxidant (19). Thus, it is not
surprising that no differences between groups were found in
lipid peroxidation. Also, X/XO does not seem to be responsible
for any kind of lipid peroxidation (54). The same perspective
can justify the observed absence in our work of significant
differences in protein carbonylation. The oxidation products of
adrenaline are thought to directly react with the nucleophilic
compounds and remain bound.
The oxidation of adrenaline will form products other than
adrenochrome (Figure 5) (19, 28). It seems, in the model adopted
in this work, that the amount and nature of adrenaline oxidation
products formed were related to the stability of the intermediary
quinone (Figure 5). Thus, a less oxidizing medium favored the
existence of quinones and their products, while in an oxidizing
medium (created by X/XO), the formation of adrenochrome is
favored, since the oxidative pathway of leucoadrenochrome is
faster (60).
The work of Miyazaki et al. (25) using tyrosinase null mice
strengthens our hypothesis. Tyrosinase present in wild mice
induces rapid oxidation of dopamine to form stable melanin,
with dopamine quinone as an intermediate. In contrast, in
tyrosinase null mice, the values for quinoproteins are higher,
since, in these animals, quinones are more stable (25).
In our work, levels of quinoproteins in ADR cells are superior
to those treated with ADR and X/XO (Figure 1C). These results
suggest that the stability of the quinone intermediate is higher
in the absence of ROS, allowing the quinone to further react
with cellular groups, while in the presence of ROS, adrenaline
is rapidly converted into more oxidized species, namely,
adrenochrome and its metabolites. Quinones, by themselves, are
reported to induce cytotoxicity, immunotoxicity, and carcino-
genesis in vivo (61, 62). The mechanisms of toxicity are diverse,
depending on their chemical structure and the cellular environ-
ment in which they are formed. In addition, alkylation of cellular
nucleophiles (GSH, proteins, and DNA) by these species may
occur to a significant extent, forming covalent adducts that can
significantly compromise cellular integrity and function (25, 38,
61). Thus, the reactivity of adrenaline toward glutathione was
evaluated. We observed a time-dependent decline in the level
of GSH in cells exposed to ADR, which was potentiated in cells
treated with ADR and X/XO (Figure 2). In both groups, the
decrease in GSH levels was not accompanied by changes in
the activities of the enzymes involved in GSH metabolism or
in the GSSG levels, leading to the hypothesis of the occurrence
of GSH conjugation with electrophilic compounds. The deple-
tion of intracellular GSH as a result of the catecholamine
oxidation process has been previously described (28, 36, 40),
and it increases the cellular vulnerability to further oxidative
injury. This fact can be of relevance during cardiopathologic
events in humans, since GSH is the major nonproteic antioxidant
present in the cells and reacts with several electrophilic
compounds.
Although adducts of GSH and dopamine or catechol me-
tabolites of MDMA have already been described (24, 41), until
now no GSH–adrenaline adducts had been reported in cells.
The rate of cyclization of adrenaline o-quinone was probably
considered to be too fast for that to occur (27). We report, for
the first time, the detection of 5-(glutathion-S-yl)adrenaline in
cardiomyocytes, even for adrenaline concentrations as low as
25 µM.
The o-quinone formed during the adrenaline oxidation process
(51), in the presence of GSH, may conjugate to form glutathio-
nyl adducts (63) (Figure 5). The catechol thioether formed by
the addition of the sulfur atom to the quinone ring (62) may be
much more redox active than an unsubstituted quinone
(34, 62, 64). This capacity to further oxidize may improve their
ability to undergo a redox cycle (62), which contributes to the
cytotoxicity of these adducts (24, 29, 61, 64). GSH conjugates
were found to covalently bind with DNA, raising the question
of their ability to cause carcinogenicity (62, 64). They were
also reported as nephrotoxic (30, 62) and neurotoxic (24, 31, 62)
compounds.
The measurement of these compounds (adduct of glutathione
and quinoproteins) is an index of oxidation of the parent
catechol, but also a direct measurement of nucleophilic modi-
fication. The selective increase in the levels of the GSH–
adrenaline adduct and quinoproteins in the groups exposed to
ADR suggest that these reactions are favored where quinone is
more stable (19, 25). This was the case for the levels of the
GSH adduct in the cells, but also in the incubation medium.
The high values of 5-(glutathion-S-yl)adrenaline in the incuba-
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tion medium of both groups exposed to adrenaline may suggest
a possible mechanism of GSH conjugate efflux in cardiomyo-
cytes (65).
In conclusion, our study has provided several lines of
evidence suggesting that an increased rate of adrenaline oxida-
tion is associated with cardiotoxicity and that the adrenaline
oxidation pathway depends greatly on the surrounding medium.
The catecholamine oxidation products are able to form covalent
bounds with the cellular nucleophilic groups (belonging to either
GSH or macromolecules). Adrenaline-induced modifications to
the protein structure may result in alteration of the cellular
function, although decreases in ATP levels or increases in the
rate of cell death were not observed in this work. The findings
of our work may prove to be important in clarifying adrenaline-
induced toxicity but also in highlighting its oxidation pathway
in a cellular medium and the influence of the microenvironment
where it occurs.
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